Overview

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy

Status:
Enrolling by invitation

Trial end date:
2023-12-01

Target enrollment:
0

Participant gender:
All

Summary

This study will evaluate the long-term efficacy and safety of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Axsome Therapeutics, Inc.

Treatments:

Reboxetine

Criteria

Inclusion Criteria:

- Completed the treatment period of Study AXS-12-301

- Willing and able to comply with the study requirements

Exclusion Criteria:

- Significant change in medical history or concomitant medications since enrolling in
the AXS-12-301 study which, in the opinion of the Investigator, would render the
subject unsuitable to receive AXS-12